Lack of efficacy of psychological and pharmacological treatments of disorders of eating behavior: neurobiological background

Francesca Brambilla¹*, Federico Amianto², Riccardo Dalle Grave³ and Secondo Fassino²

Abstract

Background: Treatments of eating disorders result too often in partial psychological and physical remission, chronicization, dropout, relapse and death, with no fully known explanations for this failure. In order to clarify this problem, we conducted three studies to identify the biochemical background of cognitive-behavioural psychotherapy (CBT), individual psychology brief psychotherapy (IBPP), and psychotherapy-pharmacotherapy with CBT + olanzapine in anorexics (AN) and bulims (BN) by measuring the levels of plasma homovanillic acid (HVA) for dopamine secretion, plasma 3-methoxy-4-hydroxy-phenylglycol (MHPG) for noradrenalin secretion, and platelet [3H]-Paroxetin-binding Bmax and Kd for serotonin transporter function. The data were then compared with psychopathological and physical alterations.

Methods: Study 1 investigated the effects of 4 months of CBT on plasma HVA, MHPG and [3H]-Par-binding in 14 AN-restricted, 14 AN-bingeing/purging, and 22 BN inpatients. Study 2 investigated the effects of 4 months of IBPP on plasma HVA in 15 AN and 17 BN outpatients. Study 3 investigated the effect of 3 months of CBT + olanzapine (5 mg/day) in 30 AN outpatients. The data were analyzed using one-way ANOVA for repeated measures for the changes between basal and post-treatment biological and psychological parameters, two-way ANOVA for repeated measures for the differences in the psychobiological data in the 3 groups, Spearman’s test for the correlations between basal and final changes in the psychological and biological scores.

Results: Study 1 revealed significant amelioration of the psychopathology in the AN and BN patients, no effects on HVA, MHPG or Paroxetine binding Kd, and a significant increase in Par-binding Bmax only in the BN patients. Study 2 revealed a significant effect of IBPP on psychopathology in the AN and BN patients, and a significant increase in HVA only in the BN patients. Study 3 revealed a significant positive effect of CBT + olanzapine therapy on the psychopathology and increased HVA values. No correlations were observed in the 3 groups between biological and psychological effects of the three treatments.

Conclusions: Our data advance suggestions on the mechanism of action of the three therapies; however, the lack of correlations between biochemical and psychological effects casts doubt on their significance. Clinical Trials.gov. Identifier NCT01990755.

Keywords: Anorexia nervosa, Bulimia nervosa, Psychotherapy, Pharmacotherapy, Biology

* Correspondence: francesca.brambilla4@tin.it
1 The University Department of Psychiatry, San Paolo Hospital, Milano, Italy
Full list of author information is available at the end of the article

© 2015 Brambilla et al; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

The treatment of Eating Disorders (ED), including anorexia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED), is a complex multivariate process which comprises nutritional rehabilitation, psychotherapy, psychopharmacotherapy, and treatment of the medical complications that develop during the course of the disease and that may interfere with its development and prognosis [1-5]. Each treatment is directed at correcting distinct parts of the disorders and each is essential for successful outcome, none being omnivalent or sufficient by itself to induce full recovery, though combined use of multiple therapies is reported to be effective in the treatment of ED. However, they mostly correct the pathological eating behaviour, often leaving out the psychological background which is the likely cause of the diseases. In other words, each treatment takes into consideration a group of symptoms or specific aspects but not the core of the diseases. This may be because the basic cause or the core of ED is still not clear. And in spite of extensive of brain imaging studies identifying the areas of hypo- or hyperfunction, but less is known about the biochemical impairments that occur with regard to the role neurotransmitters, neurohormones, neuropeptides and most of their receptors in these areas play in the psychopathological alterations related to these syndromes. Hence, the pathogenetic treatment of AN, BN and BED remains a matter of debate. Should DEB be corrected, if possible, by modifying the genetic impairments and the brain's biochemical alterations that might be the background of the disorders or just by dealing with the full-blown symptomatology of ED?

Up to now, most treatments have included behavioural and physical rehabilitation, taking into consideration correction of the distorted eating attitude but only partially the psychological impairments behind it. Whatever the therapeutic approach, the results are generally insufficient and the recovery partial, followed too often by relapses and chronicization of the diseases.

At this point, a possible validation of specific therapeutic interventions should first include investigation of the brain's biochemical impairments that have been reported to consistently occur in ED to see whether and how they correlate with the psychopathology of the disorders, and whether they change or disappear during or after treatment, in parallel with specifically correlated psychopathological aspects, ultimately resulting in full contemporary recovery of the psychopathological, behavioural and physical alterations of the diseases.

Following this line of reasoning, we conducted three types of experiments in which we looked at the psychopathological, behavioural and physical aspects of ED and, in parallel, at the concentrations of the peripheral metabolites of noradrenalin and dopamine and at serotonin function, as expressed by the serotonin transporter evaluated by platelet paroxetine binding, before and after psychotherapeutic, psychopharmacological and physical treatments. Our aim was to see whether or not it was possible to find a connection between the brain's biochemical impairments and specific psychopathological aspects of the diseases, and whether our treatments could correct the brain neurotransmitter alterations in parallel with the psychophysical pathology of the diseases.

Methods

Study 1

The first study investigated the effects of nutritional rehabilitation associated with Fairburn transdiagnostic cognitive-behavioural therapy (CBT) [18], as adapted to make it suitable for an inpatient setting by Dalle Grave [19], on the secretion of brain dopamine (DA), noradrenalin (NE) and serotonin (5-HT) in a group of 50 female inpatients, 14 with AN restricted type (AN-R), 14 with the bingeing-purging type (AN-BP), and 22 with BN. Written informed consent for participation in the study was obtained from participants. Patients were all hospitalized at Villa Garda, Garda, Italy. The study was performed in compliance with the Helsinki declaration and the approval of the hospital ethics committee. The brain neurotransmitter functions were examined by peripheral measurement of the main neurotransmitter metabolites: plasma homovanillic acid (HVA) for DA; plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) for NE; and for 5-HT the platelet 5-HT-transporter evaluated by paroxetine binding ([3H ]-Par-binding), divided in Bmax (maximum binding capacity) and Kd (dissociation constant). HVA, MHPG, and Par-binding values have been amply demonstrated to closely mirror the central secretion of the three
neurotransmitters and can be used as a correct peripheral measure of neurotransmitter function [20-23]. The aim of the study was to see whether or not NE-DA neurotransmitter metabolites and [3H]-Par-binding are linked to specific aspects of the two diseases, if CBT modifies their secretion, if the physical, behavioural and psychological effects of CBT correlate with changes in neurotransmitter secretions, and if the biological effects of CBT are linked to specific psychopathological aspects of the disorders.

All 50 patients were women. The mean age of patients was 27 ± 7 years in the AN-R group, 22 ± 4 years in the AN-BP group, and 30 ± 8 years in the BN group. The mean duration of disease was 126 ± 50 months in the AN-R group, 120 ± 72 months in the AN-BP group, and 108 ± 60 months in the BN group. The mean body-mass index ([BMI]) was 14 ± 1 in the AN-R group, 16 in the AN-BP group, and 19 in the BN group; the mean bingeing-purging frequency was 10 episodes a week in the AN-BP group and 16 episodes a week in the BN group. All the AN patients were amenorrheic, BN patients were in the follicular phase of the cycle.

The specific psychopathological aspects of the disorders were assessed according to the following instruments: EDE 12-OD, depression by the Beck Depression Inventory (BDI), anxiety by the STAI Form-Y-1, impulsiveness by the Barratt Impulsiveness Scale version 11 (BIS 11), self-esteem by the Rosenberg Self-Biochemical Scale (RSBS), and personality characteristics by the Temperament and Character Inventory-Cloninger Scale (TCI, short form of the 240 items). The biological, physical and psychological measures were assessed at baseline and at the end of 20 weeks of CBT treatment divided into 13 weeks of inpatient treatment followed by 7 weeks of residential day-hospital.

Written informed consent to participate to the study according to the Helsinki declaration was obtained from all subjects. The study protocol was approved by the institutional Review Board of Villa Garda Hospital, Verona, Italy. The Clinical Trials.gov. Identifier number was NCT01990755.

HVA and MHPG were measured by high liquid gas chromatography (HPLC) followed by dual-electrode colorimetric electrochemical detection as previously described [24]. [3H] Par binding was measured by spectrometry according to the method of Marazziti et al. [20] as previously described.

The Clinical Trials.gov. identifier number was NCT 01990755.

Study 2
This study investigated the effects in 15 AN and 17 BN outpatients of the Psychiatry University Department, Torino-Italy of an individual psychology brief psychotherapy (IBPP) [25] on psychological alterations and DA secretion measured as peripheral blood values of HVA before and after treatment. The study was performed in compliance with the Helsinki declaration, and approved by the university ethics committee.

The mean age of the patients was 20 ± 3.5 years in the AN group and 22 ± 2.8 years in the BN group. The mean duration of disease was 13 ± 8 years in the AN group and 11 ± 4 years in the BN group. The mean BMI was 16 ± 1 in the AN group and 21 ± 2 in the BN group. The duration of IBPP was 4 months. The psychopathological aspects were assessed using the EDI-2, SCL-90, TCI at baseline and after 4 months of therapy. Written informed consent for participation in the study according to the Helsinki declaration was obtained from all subjects. The study protocol was approved by the institutional Review Board of the Psychiatry Department, Turin University, Italy. The Clinical Trials.gov.Identifier number was NCT01990755.

Study 3
The study evaluated in AN-R and AN-BP patients of the San Paol Hospital, Milan, Italy, the effects of CBT and of CBT associated with orally administered 5 mg olanzapine on the psychopathological aspects of the disease and on the secretion of HVA to see whether a correlation could be observed between biochemical and psychological disorders typical of ED. The study was performed in compliance with the Helsinki declaration and approved by the hospital ethics committee.

The probands were 18 AN-R and 12 AN-BP patients of the University Dept. of Psychiatry, Milano, Italy. Mean age of the participants was 25 ± 6 years; the mean duration of disease was 5.5 ± 4 years; and the mean BMI was 15 ± 1. All were outpatients and all underwent a 3-month course of CBT, with one half randomly assigned and double-blinded to receive oral olanzapine (2.5 mg for 1 month, 5 mg for 2 months) and the other half an oral placebo. BMI, HVA and psychopathological aspects of the patients were monitored before and at 3 months of therapy by means of the EDI-2, the Hamilton Rating Scale for Depression (HRSD), the Buss-Durkee Rating Scale for aggressiveness (BDRS), the TCI for temperament and character aspects, and the Yale-Brown Cornell for Eating Disorders (YBCS) for obsessivity-compulsivity.

Written informed consent to participate to the study according to the Helsinki declaration was obtained from all subjects. The study protocol was approved by the Institutional Review Board of The Sacco Hospital, Milano, Italy.

The Clinical Trials.gov.Identifier number was NCT 01990755.

Statistical analyses
The data were analyzed using one-way ANOVA for repeated measures to evaluate the significance of the
changes in biological and psychological parameters between baseline and post-treatment, and by two-way ANOVA for repeated measures to evaluate the differences in the psychological and biological data in the three groups. The Spearman test was used to evaluate the correlations between basal and final changes in the psychological and biological scores.

Results

Study 1

CBT significantly improved the physical aspects of the diseases, particularly BMI in the AN-R and AN-BP patients, and significantly reduced or totally interrupted binging-purging frequency in the AN-BP and BN patients. Psychological assessment revealed that at the end of treatment the ED symptoms, depression, anxiety, impulsiveness and self-esteem improved across all three groups, but more significantly so in the BN than in the AN group. The basal (T0) and final (T1) HVA and MHPG values (Table 1) did not differ significantly in the three groups and decreased but not significantly in all three groups after the end of CBT. Basal and final Par-binding Bmax values did not differ significantly in the three groups and did not change significantly in the AN-R and AN-BP patients, whereas a significant increase was observed in the BN patients. Basal and final Par-binding Kd did not differ significantly in the three groups, and no significant changes were observed in any of the three groups between basal and final values. Basal and final psychological and biochemical data did not correlate. When the difference (Δ) between the basal and final values of neurotransmitter and psychological scores was taken into consideration, no significant correlations were observed between the psychological and the biochemical data.

Study 2

At the end of treatment with IBPP the BMI increased significantly over baseline in the AN patients (16 ± 1 vs. 21 ± 2, P < 0.001) but was unchanged in the BN patients. Bingeing-purging frequency was consistently reduced in both the AN and BN groups. Psychological impairments after therapy improved in both the AN and BN groups. With regard to the biochemical data (Table 2), HVA values before therapy did not differ in the AN and BN patients and did not change after treatment in the AN patients but increased significantly in the BN patients. No significant correlations were observed between the psychometric test scores and the HVA values before and after therapy, nor between the changes in two parameters between the two time points, except for some temperamental aspects whose changes showed a positive correlation with those of the DA metabolite, as represented by reward dependence in particular (P < 0.02) in both the AN and BN patients, harm avoidance in the AN (P < 0.04) and BN patients (P < 0.008), self-directedness in the BN patients (P < 0.04), self-transcendence in the BN patients (P < 0.007) and cooperativeness in the AN and BN patients (P < 0.06).

Study 3

At the end of 3 months of treatment with CBT and olanzapine (Table 3), the BMI increased consistently in the AN patients without a significant difference between the CBT and the CBT + olanzapine-treated patients (16.2 ± 1 vs. 21.4 ± 2; P > 0.001). Bingeing-purging frequency was also reduced. The psychopathological symptoms including most of the specific aspects related to eating pathology of the disease improved consistently with both treatments, albeit without significant differences between the two groups, while olanzapine administration significantly improved obsessivity-compulsivity, depression, anxiety and especially hostility (Table 3). HVA blood levels increased significantly in the CBT + olanzapine group, and were unchanged in the CBT group. No correlations were observed between HVA concentrations and the psychopathological parameters examined before and after therapy, nor the changes between the two parameters.

Discussion

Even though preliminary the results of our three studies are intriguing. In each of them the psychopathology and

---

Table 1 Effects of CBT on HVA, MHPG and [3H]paroxetine-binding values in AN and BN patients

|                | AN-R | AN-BP | BN     |
|----------------|------|-------|--------|
| HVA (ng/ml)    |      |       |        |
| basal          | 17.4 ± 9.0 | 16.6 ± 8.8 | 15.6 ± 10.2 |
| after therapy  | 15.6 ± 9.8 | 12.7 ± 6.0 | 14.1 ± 9.6 |
| MHPG (ng/ml)   |      |       |        |
| basal          | 10.4 ± 27.1 | 5.3 ± 4.0 | 4.4 ± 1.9 |
| after therapy  | 4.4 ± 4.2 | 4.1 ± 3.8 | 3.4 ± 1.7 |
| [3H]-PAR-Bmax (fmol/mg protein) |      |       |        |
| basal          | 446 ± 100 | 512 ± 175 | 432 ± 133 |
| after therapy  | 602 ± 161 | 551 ± 306 | 645 ± 121* |
| [3H]-PAR-Kd (nmol/L) |      |       |        |
| basal          | 0.34 ± 0.48 | 0.31 ± 0.43 | 0.26 ± 0.34 |
| after therapy  | 0.24 ± 0.38 | 0.64 ± 0.14 | 0.05 ± 0.004 |

Plus-minus values are the means ± SD.

*p = 0.04, r = 1.

---

Table 2 Effects of IBPP therapy on HVA secretion in AN and BN patients

|                | AN     | BN     |
|----------------|--------|--------|
| basal          | 6.9 ± 2.3 | 8.1 ± 1.8 |
| after therapy  | 7.6 ± 1.6 | 11.3 ± 3.3* |

*p < 0.000.

Plus-minus values are the means ± SD.
the behavioural alterations were significantly improved by CBT or IBPP in the bulimics and somewhat less in the anorexics, while olanzapine treatment seemed to act significantly mostly on comorbid depression, anxiety, obsessivity-compulsivity and hostility, suggesting that a dopaminergic deficiency could be the background of comorbidities more than of a specific ED symptomatology.

However, the effects of the three treatments on NE, DA and 5-HT functions are difficult to interpret. The HVA and MHPG values in Study 1 did not change under CBT in either the AN or BN patients, suggesting that the therapeutic effects of this type of psychotherapy are probably not related to catecholamine function, and that the observed improvements in the altered nutritional behaviour and related psychopathology may not be linked to increases in previously deficient NE and DA secretions. This was suggested also by the observation that when the basal and post-treatment neurotransmitter \( \Delta \)-values and \( \Delta \)-psychological scores were correlated no significant correlations were observed between \( \Delta \)-HVA or \( \Delta \)-MHPG and \( \Delta \)-psychopathological aspects of the diseases. With regard to [3H]-Paroxetine-binding Bmax and Kd, the observation that CBT increased 5-HT transporter maximum binding capacity in the BN but not in the AN patients is interesting, since impaired 5-HT brain function has been reported in both AN and BN patients but only BN patients have been reported to show a clear-cut psychopathological recovery after psychotherapy [5,23,26-29], which could be related to the 5-HT transporter improvement we observed. The fact that we could not find specific significant correlations between improvement in 5-HT function and a significant reduction in ED psychopathology in the bulimics, however, seems to exclude that the positive psychophysical effects of CBT are linked to a global correction of 5-HT function.

Two points seem to contradict the correction secretory hypothesis. First, the Par-binding improvement is incomplete regarding the binding capacity of the transporter but not its dissociation constant, thus casting doubt on a global regulatory effect of CBT on 5-HT. Second, the lack of a correlation between the Par-binding-Bmax increase and improvement in BN-specific psychopathology of our patients would suggest that the two improvements, biological and psychopathological, are not linked to one another and therefore that the BN-specific psychological alterations are not linked to a serotonin deficiency. It should be remarked that the rating scales we used to measure the psychopathology of our patients may have missed important aspects of BN and that correlations between 5-HT secretion and clinical symptoms might have appeared if other aspects of the disorder had been taken into consideration. The same observation holds for the type of assay of 5-HT function we used, since Par-binding measures the function of 5-HT transporter and not the direct secretion of 5-HT and its metabolites, 5-HT receptors density and function. All these points should be considered and investigated to evaluate the meaning of our results.

The data from Study 2 are also intriguing. While IBPP was frankly effective on the psychological and behavioural alterations of both AN and BN patients, no changes were observed in HVA secretion in the AN patients, while increased secretion of the DA metabolite was observed in the BN patients. Again, no correlations between the biochemical and psychological aspects of the disorders were observed in either group, except for temperamental characters whose changes under the IBPP therapy revealed a positive correlation with the increase in HVA in both groups. Hence, it may be conjectured that a DA deficiency in AN and BN is not involved in their specific psychological and behavioural pathologies, being instead the possible background of the temperamental alterations which, on the other hand, have been suggested as one of the basic components in ED etiopathogenesis. Obviously, the same objections to our methodology reported for Study 1 can be raised here too. In both studies we used a large variety of rating scales to investigate the entire spectrum of the psychopathological aspects of AN and BN, including the premorbid temperamental characters of the patients, and the psychological, behavioural and comorbid aspects of the full-blown AN and BN pathologies. This does not exclude that our investigation might have missed other psychopathological aspects more significantly improved by IBPP treatment and possibly better correlating with a DA-dependent psychopathology. Moreover, HVA is a mirror of DA secretion but not of DA pre- and postsynaptic receptor activity, which means that we cannot exclude an effect of IBPP on DA system function and aspects we did not take into consideration.

The results of Study 3 are even more intriguing. While CBT significantly improved the specific psychopathology of our patients, olanzapine administration seemed to act mostly on the associated comorbidities like depression, anxiety, hostility and obsessivity-compulsivity. Again, a lack of correlation between increased DA activity and decreased AN-specific and unspecific psychopathology seems to exclude the possibility that a DA dysfunction in AN is involved in the pathogenesis of the disorder and its possible recovery. Altered DA secretion has been suggested to be involved in the etiopathogenesis of ED.

### Table 3 Effect of CBT + olanzapine or placebo on HVA secretion in anorexia nervosa

| Patients | T0   | T1   | p    | F    | d.f |
|----------|------|------|------|------|-----|
| Olanzapine | 0.4 ± 0.3 | 1.1 ± 1.5 | 0.04 | 3.6  | 3   |
| Placebo   | 0.4 ± 0.1 | 0.3 ± 0.1 | NS   |      |     |

Plus-minus values are the means ± SD.
symptomatology [6,7,9,30-34]. However, specific treatments in the past with classical psychotropic drugs acting on DA secretion and receptor functions have not yielded positive results [5,35-37]. More recently, atypical psychotropic drugs including olanzapine, quetiapine, risperidol, clozapine, aripiprazole have been administered [5,38], again, with inconsistent effects. In these therapeutic approaches, drug absorption and its effects on manipulating DA secretion and DA receptor response were not controlled. Study 3 demonstrated that while olanzapine does stimulate DA secretion it does not seem to influence AN-specific psychopathology. But as we did not investigate its pre- and postsynaptic receptor function, we cannot exclude that the lack of efficacy of the drug was not due to postsynaptic receptor insensitivity.

Limits of our studies include the relatively small samples of patients examined, which reduces the generalization of the results and did not permit the subgrouping of the samples in the diagnostic subtypes. A second limit is represented by the choice of running each experiment in different centres. This was due to the necessity of finding in a relatively short time a sufficient number of patients with a perfectly well defined diagnosis.

Conclusions
At this point we should admit that our approach did not fully elucidate the biochemical impairments potentially underlying ED nor did it further our understanding of the background and significance of the effects of our therapeutic approaches. In particular, we were unable to define clear-cut correlations between the therapeutically-induced changes of basal NE, DA and 5-HT metabolites and of the specific psychopathological aspects of the two disorders. In brief, our protocol of investigation did not help us to better define the brain biochemical background of ED therapies or provide convincing evidence for which type of therapy to suggest. Possibly, other biochemical alterations should be examined in parallel, including hormones, peptides, multiple biochemical parameters expressions of the brain metabolic function together with anatomical alterations of specific brain centers. In other words, a protocol of investigation including the relationship between biochemical and psychological aspects of the patients should be always at the basis of the diagnostic and therapeutic approaches to ED.

Competing interests
1. In the past five years none of the authors received reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future. No organizations financed this manuscript. None of the authors old any stocks or shares in an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future.
2. None of the authors hold or are currently applying for any patents relating to the content of the manuscript. We have received no reimbursements, fees, funding, or salaries from an organization that holds or has applied for patents relating to the content of the manuscript.

3. None of the authors have any other financial competing interests.
4. None of the authors have any non-financial competing interests (political, personal, religious ideological, academic, intellectual, commercial or any other) to declare in relation to this manuscript.

Authors’ contributions
FB conceived the study, made the literature research, the design of the study, the protocol of the 3 researches, selected and treated the patients of study 3, made their assays, the statistical analyses, drafted the manuscript. RDG contributed to the design of the study, selected and treated patients of study 1, made their assays, read and approved the manuscript. FA contributed to the selection and treatment of the patients of study 2, made their assays, read and approved the manuscript. SF contributed to the selection and treatment of the patients of study 2, made their assays, read and approved the manuscript. All authors read and approved the final manuscript.

Acknowledgment
Nobody contributed towards the article by making substantial contributions to conception, design, acquisition, analysis or interpretation of data, or was involved in drafting the manuscript or revising it critically for important intellectual content.

None of the authors received funding bodies and nobody provided medical writing services.

Author details
1 The University Department of Psychiatry, San Paolo Hospital, Milano, Italy.
2 University Department of Psychiatry, Torino, Italy. 3 Department of Eating Disorders, Villa Garda, Garda, Italy.

Received: 18 May 2013 Accepted: 19 December 2014
Published online: 24 December 2014

References
1. NICE Eating Disorders-Core Interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related eating disorders. In: NICE Clinical Guideline No. 9, National Institute for Clinical Excellence/ Gaskell and the British Psychological Society, London;London, 2011.
2. Wilson TJ, Fairburn GC. Treatment for Eating Disorder: In A Guide to Treatments that Work. Edited by Nathan PE, Gorman JM. New York: Oxford University Press, 2007.
3. Fairburn CG, Cooper Z, O’Connor ME, Bohn K, Hawker DM, Wales JA, Palmer RL: Transdiagnostic Cognitive-Behavioral Therapy for patients with Eating Disorders: a two-site trial with 60-week follow-up. Am J Psychiatry 2009, 166(3):311–319.
4. Safer DL, Robinson AH, Jo B: Outcome from a randomized controlled trial of group therapy for Binge Eating disorder: comparing Dialectical Behavior Therapy adapted for Binge Eating to an Active Comparison group therapy. Behav Ther 2010, 41:106–120.
5. Aigner M, Treasure J, Kaye W, Kasper S, WFSBP Task Force On Eating Disorders: World Federation Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Eating Disorders. World J Biol Psychiatr 2011, 12:400–443.
6. Kaye WH, Frank GK, McConaha C: Altered dopamine activity after recovery from restricting-type anorexia nervosa. Neuropsychopharmacol 1999, 21:503–506.
7. Frank GK, Bailer UF, Henry SE, Drevets V, Meltzer CC, Price JC, Mathis CA, Wagner A, Hoge J, Ziozk S, Barbarich-Martellier N, Weissfeld L, Kaye WH: Increased dopamine D2/D3 receptor binding after recovery from anorexia nervosa measured by positron emission tomography and 11C-raclopride. Biol Psychiatr 2005, 58:908–912.
8. Wagner A, Alzertsen H, Mazurkewicz L, Fudge J, Frank GK, Putnam K, Bailer UF, Fischer L, Kaye WH: Altered insula response to taste stimuli in anorexia nervosa. Neuropsychopharmacol 2008, 33:13–523.
9. Kaye WH, Ebert MH, Raleigh M, Lake R: Abnormalities in CNS monoamine metabolism in anorexia nervosa. Arch Gen Psychiatr 1984, 41:350–355.
10. Kaye WH, Gwirtsman HE, George DT, Ebert H: 5-HIAA concentrations in anorexia nervosa: reduced values in underweight subjects normalize after weight gain. Biol Psychiatr 1988, 23:102–105.
Neuroleptics in the short-term treatment of anorexia nervosa after long-term weight recovery. Arch Gen Psychiat 1991, 48:556–562.

12. Kaye WH, Frank GK, Meltzer CC, Price JC, McGonaha CW, Crossan PJ, Klump KL, Rhodes L: Altered serotonin 2A receptor activity in women who have recovered from bulimia nervosa. Am J Psychiatr 2001, 158:1152–1155.

13. Kaye WH, Barbarich KC, Robinson KA, Fernstrom J, Fernstrom M, McGonaha CV, Kishore A: Anxiolitic effects of acute tryptophan depletion in anorexia nervosa. Int J Eat Dis 2003, 32:257–267.

14. Brambilla F, Bellodi L, Aranico C, Ronchi P, Limonta D: Central dopaminergic function in anorexia and bulimia nervosa: a psychoneuroendocrine approach. Psychoneuroendocrinology 2001, 26:399–409.

15. Bailer UF, Price JC, Meltzer CC, Becker C, Mathis CA, Wagner A, Barbarich-Martsteller NC, Platz S, Putman K, Schork NJ, Kaye WH: Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa. Psychiatr Res 2013, 211:160–168.

16. Fairburn CG, Harrison PJ: Eating Disorders. Lancet 2003, 361:407–416.

17. Dalle Grave R: A multiple-step cognitive behaviour therapy for eating disorders. Eat Dis Rev 2005, 13:372–382.

18. Marazziti D: Anxiety in anorexia and bulimia nervosa: a psychological approach. J Clin Psychopharmacol 1994, 14:404–408.

19. Rausch J, Johnson ME, Li J, Hutcheson J, Carr BM, Corley KM, Gowan AB, Henry SE, Brooks-Achenbach S, Barbarich NC, Kaye WH: Altered 5-HT2A receptor binding after recovery from bulimia-type anorexia nervosa: relationship to harm avoidance and drive for thinness. Neuropsychopharmacology 2004, 29:143–155.

20. Marazziti D, Pertughi G, Delitto J, Lenzi A, Maremmani I, Pacidi GF, Cassano GB: High-affinity 3H-imipamine binding sites: a possible state-dependent marker for major depression. Psychiatr Res 1988, 23:229–237.

21. Sternberg DE, Heninger GR, Roth RH: Plasma homovanillic acid as an index of brain dopamine metabolism: Enhancement with debrisoquin. Life Sci 1983, 32:2447–2452.

22. Glaizer WM, Charney DS, Heninger GR: Noradrenergic function in schizophrenia. Arch Gen Psychiatr 1987, 44:898–904.

23. Rausch J, Johnson ME, Li J, Hutcheson J, Carr BM, Coley KM, Gowan AB, Smith J: Serotonin transporter kinetics correlated between human platelets and brain synaptosomes. Psychopharmacol 2005, 180:391–398.

24. Fassino S, Amianto F, Ferrero A: Brief Adlerian psychodynamic psychotherapy: theoretical issues and process indicators. Panninerva Med 2008, 58:163–175.

25. Gerhardt GA, Diedrich CJ, Freedman P: Simultaneous determination of free homovanillic acid (HVA), 3-methoxy-4-hydroxyphenylglycol (MHPG) and vanillylamide with human plasma by HPLC coupled with dual electrode coulometric electrochemical detection. Anal Chem 1986, 58:2879–2883.

26. Monteleone P, Brambilla F, Bortolotti L, LaRocca A, Maj M: Prolactin response to d-fenfluramine is blunted in people with anorexia nervosa. Brit J Psychiatr 1998, 172:418–422.

27. Favaro A, Caregari L, Burina AB, Santonastaso P: Tryptophan levels, excessive exercise, and nutritional status in anorexia nervosa. Psychosom Med 2000, 65:535–538.

28. Bruce KR, Steiger H, NG Ying Kin NMK, Israel M: Reduced platelet [3H]paroxetine binding in anorexia nervosa: relationship to eating symptoms and personality pathology. Psychiatr Res 2006, 142:225–232.

29. Eckman A, Sandblad-Everfors C, Landéen M, Eriksson T, Eriksson E: Low density and high affinity of platelet [3H]paroxetine-binding in women with bulimia nervosa. Psychiatr Res 2006, 142:19–233.

30. Halmi KA, Dekirmenjian H, Davis J, Helzer J, Goldberg S: Catecholamine metabolism in anorexia nervosa. Arch Gen Psychiatr 1978, 35:438–460.

31. Jimerson DC, Lesem MD, Kaye WH, Breslow TD: Symptom severity and neurotransmitter studies in bulimia. Psychopharmacol 1988, 96:24–129.

32. Brambilla F, Bellodi L, Aranico C, Ronchi P, Limonta D: Central dopaminergic function in anorexia and bulimia nervosa: a psychoneuroendocrine approach. Psychoneuroendocrinol 2001, 26:393–409.

33. Castru Formiello J, Deauleo F, Barba I, Casalú V, Saura B, Labaro L, Pulj J, Toro J, Bernardo M: Psychopathological and nutritional correlates of plasma homovanillic acid in adolescent with anorexia nervosa. J Psychiatr Res 2008, 42:213–220.

34. Kaye W: Neurobiology of anorexia and bulimia nervosa. Physiol Behav 2008, 94:121–135.

35. Vandereiken W, Piere H: Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled cross-over study. Acta Psychiatr Scand 1982, 66:445–450.

36. Vandereiken W: Neuroleptics in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled study with sulpiride. Brit J Psychiatr 1984, 144:288–292.

37. Cassano GB, Minni M, Pini S, Rotondo A, Banti S, Boni C, Camilleri V, Mauri M: Six-month open trial of haloperidol as an adjunctive treatment for anorexia nervosa: a preliminary report. Int J Eat Dis 2003, 33:72–117.

38. Mondray N, Birmingham CL, Touzi S, Sundakow V, Chapman L, Beaumont P: Randomized controlled trial of olanzapine in the treatment of outpatients with bulimia nervosa. J Clin Psychopharmacol 2005, 13:72–75.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or figure charge figures
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit